Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...
Novartis AG (NOVN) Gets a Buy from Kepler Capital
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...
American Association of Individual Investors11h
Why Molecular Partners AG’s (MOLN) Stock Is Up 9.28%
Molecular Partners AG’s MOLN share price has surged by 9.28%, which has investors questioning if this is right time to sell.
Novartis6d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Reuters8d
Novartis AG
February 25, 2025 Sandoz family foundation offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares ...
Fierce Pharma5d
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
Fierce Pharma5d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
STAT7d
Novartis finally delivers gene therapy data in older SMA patients. Will they still want it?
In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...